EARS - Auris Medical Holding AG

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.79
-0.05 (-5.95%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.84
Open0.83
Bid0.76 x 1200
Ask0.90 x 1300
Day's Range0.76 - 0.83
52 Week Range0.24 - 3.08
Volume152,082
Avg. Volume373,874
Market Cap4.833M
Beta0.34
PE Ratio (TTM)N/A
EPS (TTM)-3.70
Earnings DateNov 8, 2017 - Nov 13, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Trade prices are not sourced from all markets
  • ACCESSWIRE11 days ago

    Free Technical Reports on Arrowhead Pharma and Three Additional Biotech Equities

    On Tuesday, June 12, 2018, the NASDAQ Composite and the S&P 500 edged 0.57% and 0.17% higher, respectively at the closing bell, while the Dow Jones Industrial Average stayed bearish, finishing marginally lower by 0.01%. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), Atara Biotherapeutics Inc. (NASDAQ: ATRA), Athersys Inc. (NASDAQ: ATHX), and Auris Medical Holding AG (NASDAQ: EARS).

  • What Are The Drivers Of Auris Medical Holding AG’s (NASDAQ:EARS) Risks?
    Simply Wall St.20 days ago

    What Are The Drivers Of Auris Medical Holding AG’s (NASDAQ:EARS) Risks?

    For Auris Medical Holding AG’s (NASDAQ:EARS) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. EARS isRead More...

  • GlobeNewswire25 days ago

    Auris Medical to Host Key Opinion Leader Call Focused on AM-201 Program for Treating Major Side Effects of Antipsychotics on June 11, 2018

    Auris Medical Holding AG (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and mental health supportive care, today announced that it will host a Key Opinion Leader call for the investment community on Monday, June 11, 2018, at 8 am EDT / 2 pm CET. The event will focus on Auris Medical's clinical development program with AM-201 in the prevention or treatment of major side effects of antipsychotic drugs, notably weight gain and drowsiness (somnolence). It will feature a presentation by John M. Kane, MD, Senior Vice President for Behavioral Health Services at Northwell Health in New Hyde Park, New York.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of EARS earnings conference call or presentation 15-May-18 12:00pm GMT

    Q1 2018 Auris Medical Holding AG Earnings Call

  • Associated Presslast month

    Auris: 1Q Earnings Snapshot

    On a per-share basis, the Zug, Switzerland-based company said it had a loss of 32 cents. The company's shares closed at $1.70. A year ago, they were trading at $7.02. _____ This story was generated by ...

  • GlobeNewswirelast month

    Auris Medical Provides Business and Strategy Update and Reports First Quarter 2018 Financial Results

    Expansion of intranasal betahistine program into mental health supportive care Initiating project AM-201 for the treatment of histaminergic receptor mediated weight gain and drowsiness in patients treated ...

  • GlobeNewswirelast month

    Auris Medical to Report First Quarter 2018 Financial Results and Provide Business and Strategy Update on Tuesday, May 15, 2018

    Zug, Switzerland, May 14, 2018- Auris Medical Holding AG, a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, today announced that it ...

  • ACCESSWIRE2 months ago

    Wired News – Auris Medical Reported Publication Related to AM-111 in Peer-Reviewed Scientific Journal Hearing Research

    LONDON, UK / ACCESSWIRE / May 08, 2018 / If you want access to our free research report on Auris Medical Holding AG (NASDAQ: EARS), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=EARS as the Company's latest news hit the wire. On May 04, 2018, the Switzerland-based biopharmaceutical Company announced that the article reviewing the mechanism of action, pharmacokinetics and therapeutic applications of AM-111, the Company's investigational treatment for acute inner ear hearing loss, was published in Hearing Research, one of the leading journals in the otorhinolaryngology field. The peer-reviewed article "Preclinical and clinical otoprotective applications of cell-penetrating peptide D-JNKI-1 (AM-111)" was published.

  • Benzinga2 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Starbucks Corporation (NASDAQ: SBUX ) stock gained ...

  • GlobeNewswire2 months ago

    Auris Medical Receives Positive Scientific Advice from EMA on Development Plan and Regulatory Pathway for AM-111

    Auris Medical Holding AG (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, announced today that the Company has received positive Scientific Advice from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) related to the development plan and regulatory pathway for AM-111, its investigational treatment for acute inner ear hearing loss. The Scientific Advice (Protocol Assistance) had been requested by the Company following the results of the HEALOS phase 3 trial.

  • GlobeNewswire2 months ago

    Auris Medical Announces Publication Related to AM-111 in Peer-Reviewed Scientific Journal

    Auris Medical Holding AG (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, today announced the publication of an article reviewing the mechanism of action, pharmacokinetics and therapeutic applications of AM-111, its investigational treatment for acute inner ear hearing loss. "The publication summarizes the extensive body of non-clinical and clinical data on AM-111 that have been accumulating over more than 15 years of research", commented Thomas Meyer, Auris Medical's founder, Chairman and CEO. AM-111 is being developed in a biocompatible gel formulation for the treatment of acute sensorineural hearing loss with a single-dose administration into the middle ear.

  • GlobeNewswire2 months ago

    Auris Medical Announces Early Repayment of Part of its Loan Facility

    Zug, Switzerland, April 9, 2018- Auris Medical Holding AG, a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, today announced the voluntary ...

  • ACCESSWIRE3 months ago

    Blog Exposure - Actinium Announces Collaboration with Astellas Pharma

    Stock Monitor: Auris Medical Holding Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 02, 2018 / Active-Investors.com has just released a free research report on Actinium Pharma, Inc. (NYSE: ATNM ...

  • GlobeNewswire3 months ago

    Auris Regains Compliance with Nasdaq's Minimum Bid Price Requirement

    Zug, Switzerland, March 29, 2018- Auris Medical Holding AG, a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, today announced it received ...

  • Associated Press3 months ago

    Auris reports 4Q loss

    The Zug, Switzerland-based company said it had a loss of $1.01 per share. For the year, the company reported that its loss narrowed to $24.8 million, or $5.69 per share. The company's shares closed at ...

  • Benzinga3 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Advanced Micro Devices, Inc. (NASDAQ: AMD ) stock ...

  • What Are The Drivers Of Auris Medical Holding AG’s (NASDAQ:EARS) Risks?
    Simply Wall St.4 months ago

    What Are The Drivers Of Auris Medical Holding AG’s (NASDAQ:EARS) Risks?

    For Auris Medical Holding AG’s (NASDAQ:EARS) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. The betaRead More...